Jefferies Says Too Early to Judge the Impact of AbbVi Competition on Gilead (GILD)
Tweet Send to a Friend
Jefferies analyst Thomas Wei reiterated a Hold rating on Gilead Sciences (NASDAQ: GILD) while bumping his price target to $84.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
